Tanomastat Exerts Multi-targeted Inhibitory Effects on Viral Capsid Dissociation and RNA Replication in Human Enteroviruses

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2024 Sep 3

PMID 39226680

Authors

Therese Yien May Lim

Chaitanya K Jaladanki

Yi Hao Wong

Thinesshwary Yogarajah

Hao Fan

Justin Jang Hann Chu

Affiliations

Soon will be listed here.

Abstract

Background: Global cyclical outbreaks of human enterovirus infections has positioned human enterovirus A71 (EV-A71) as a neurotropic virus of clinical importance. However, there remains a scarcity of internationally approved antivirals and vaccines.

Methods: In pursuit of repurposing drugs for combating human enteroviruses, we employed a comprehensive pharmacophore- and molecular docking-based virtual screen targeting EV-A71 capsid protein VP1-4, 3C protease, and 3D polymerase proteins. Among 15 shortlisted ligand candidates, we dissected the inhibitory mechanism of Tanomastat in cell-based studies and evaluated its in vivo efficacy in an EV-A71-infected murine model.

Findings: We demonstrated that Tanomastat exerts dose-dependent inhibition on EV-A71 replication, with comparable efficacy profiles in enterovirus species A, B, C, and D in vitro. Time-course studies suggested that Tanomastat predominantly disrupts early process(es) of the EV-A71 replication cycle. Mechanistically, live virus particle tracking and docking predictions revealed that Tanomastat specifically impedes viral capsid dissociation, potentially via VP1 hydrophobic pocket binding. Bypassing its inhibition on entry stages, we utilized EV-A71 replication-competent, 3D replication-defective, and bicistronic IRES reporter replicons to show that Tanomastat also inhibits viral RNA replication, but not viral IRES translation. We further showed that orally administered Tanomastat achieved 85% protective therapeutic effect and alleviated clinical symptoms in EV-A71-infected neonatal mice.

Interpretation: Our study establishes Tanomastat as a broad-spectrum anti-enterovirus candidate with promising pre-clinical efficacy, warranting further testing for potential therapeutic application.

Funding: MOE Tier 2 grants (MOE-T2EP30221-0005, R571-000-068-592, R571-000-076-515, R571-000-074-733) and A∗STARBiomedical Research Council (BMRC).

References

Murray K, Nibert M . Guanidine hydrochloride inhibits mammalian orthoreovirus growth by reversibly blocking the synthesis of double-stranded RNA. J Virol. 2007; 81(9):4572-84. PMC: 1900160. DOI: 10.1128/JVI.02106-06. View

De Colibus L, Wang X, Spyrou J, Kelly J, Ren J, Grimes J . More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol. 2014; 21(3):282-288. PMC: 4530014. DOI: 10.1038/nsmb.2769. View

Yang C, Li H, Jiang J, Hsu C, Wang Y, Lai M . Enterovirus type 71 2A protease functions as a transcriptional activator in yeast. J Biomed Sci. 2010; 17:65. PMC: 2923119. DOI: 10.1186/1423-0127-17-65. View

Chen J, Ye X, Zhang X, Zhu Z, Zhang X, Xu Z . Coxsackievirus A10 atomic structure facilitating the discovery of a broad-spectrum inhibitor against human enteroviruses. Cell Discov. 2019; 5:4. PMC: 6331555. DOI: 10.1038/s41421-018-0073-7. View

Rotbart H . Antiviral therapy for enteroviruses and rhinoviruses. Antivir Chem Chemother. 2000; 11(4):261-71. DOI: 10.1177/095632020001100402. View

Rossmann M . Viral cell recognition and entry. Protein Sci. 1994; 3(10):1712-25. PMC: 2142612. DOI: 10.1002/pro.5560031010. View

Huang Y, Lin T, Wang S, Wang J . The role of conserved arginine and proline residues in enterovirus VP1 protein. J Microbiol Immunol Infect. 2022; 55(4):590-597. DOI: 10.1016/j.jmii.2022.01.004. View

Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T . Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009; 15(7):798-801. DOI: 10.1038/nm.1992. View

Wang J, Hu Y, Zheng M . Enterovirus A71 antivirals: Past, present, and future. Acta Pharm Sin B. 2022; 12(4):1542-1566. PMC: 9279511. DOI: 10.1016/j.apsb.2021.08.017. View

10.

SCHMIDT N, LENNETTE E, Ho H . An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974; 129(3):304-9. DOI: 10.1093/infdis/129.3.304. View

11.

Lu J, He Y, Yi L, Zan H, Kung H, He M . Viral kinetics of enterovirus 71 in human abdomyosarcoma cells. World J Gastroenterol. 2011; 17(36):4135-42. PMC: 3203367. DOI: 10.3748/wjg.v17.i36.4135. View

12.

Salam N, Nuti R, Sherman W . Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model. 2009; 49(10):2356-68. DOI: 10.1021/ci900212v. View

13.

Cao Y, Lei E, Li L, Ren J, He X, Yang J . Antiviral activity of Mulberroside C against enterovirus A71 in vitro and in vivo. Eur J Pharmacol. 2021; 906:174204. DOI: 10.1016/j.ejphar.2021.174204. View

14.

Tan Y, Yam W, Sun J, Chu J . An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral Res. 2017; 149:143-149. DOI: 10.1016/j.antiviral.2017.11.017. View

15.

Wu Y, Yeo A, Phoon M, Tan E, Poh C, Quak S . The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010; 14(12):e1076-81. DOI: 10.1016/j.ijid.2010.07.006. View

16.

Gunaseelan S, Wong K, Min N, Sun J, Ismail N, Tan Y . Prunin suppresses viral IRES activity and is a potential candidate for treating enterovirus A71 infection. Sci Transl Med. 2019; 11(516). DOI: 10.1126/scitranslmed.aar5759. View

17.

Solomon T, Lewthwaite P, Perera D, Cardosa M, McMinn P, Ooi M . Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010; 10(11):778-90. DOI: 10.1016/S1473-3099(10)70194-8. View

18.

Anasir M, Zarif F, Poh C . Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci. 2021; 28(1):10. PMC: 7811253. DOI: 10.1186/s12929-021-00708-8. View

19.

Friesner R, Banks J, Murphy R, Halgren T, Klicic J, Mainz D . Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7):1739-49. DOI: 10.1021/jm0306430. View

20.

Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F . In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012; 157(4):669-79. DOI: 10.1007/s00705-011-1222-6. View